US-based pharmaceutical company Merck, via its Global Health Innovation Fund, has invested $6m in Remedy Informatics, a provider of registries for healthcare and life science research, formerly known as RemedyMD.
Through the fund Merck has also invested in US-based point of care diagnostics group Daktari in a $10m round and US-based cardiovascular risk assessment company Aviir in a $30m round.
Gary Kennedy, chief executive at Remedy, said: “This additional capital will fuel our growth here in the U.S. and our expansion into Europe and Latin America, in addition it will enable us to continue to invest in our Mosaic Platform so that we can further extend our technology lead in the marketplace.”
Over the past year Remedy has entered into a series of major new customer engagements, including Cleveland Clinic’s Heart and Vascular Institute, Massachusetts General Hospital, Baylor Health Care System, Princess Margaret Cancer Centre in Toronto, Indiana University and the Indiana Clinical and Translational Science Institute, according to news provider MarketWatch.
In conjunction with the deal, Merck will now have a seat on Remedy’s board.